Mereo BioPharma Group plc (NASDAQ:MREO) 2020 Interim Financial Results Conference Call September 29, 2020 8:00 AM ET Company Participants Steve Klass - IR, Burns McClellan Denise Scots-Knight - CEO Michael Wyzga - Interim CFO John Lewicki - Chief Scientific Officer Conference Call Participants Joseph Schwartz - SVB Leerink Operator Good morning ladies and gentlemen. Thank you for standing by and welcome to the Mereo BioPharma 2020 Interim Results Conference Call. At this time, all participants are in a list ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

Mereo BioPharma Group plc (NASDAQ:MREO) 2019 Interim Financial Results and Corporate Update Conference Call September 17, 2019 8:00 AM ET Company Participants Richard Jones – Chief Financial Officer Denise Scots-Knight – Chief Executive Officer Conference Call Participants Brian White – Cantor Fitzgerald Zoe Karamanoli – RBC Capital Markets Mick Cooper – Trinity Delta Operator Good morning ladies and gentlemen. Thank you for standing by and welcome to the Mereo BioPharma 2019 Interim Results Conference Call ...

| --- | --- | --- | --- | |-------|-------------------------|-------|-------| | | | | | | | | | | | | 2019 INTERIMS CORPORATE | | | DISCLAIMER THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This presentation has been prepared by Mereo BioPharma Group plc (the "Company") solely for your information and for use at a presentation for th ...

OR Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the fiscal year ended December 31, 2018 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...